Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

50.76 +4.37 (+9.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
29 30 Next >
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Helping save and improve patients' lives in novel ways can be a lucrative activity. 
Via The Motley Fool
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead
Via Benzinga
Stocks to Watch This Week’s Top 7 Wall Street Upgrades
With the market printing some red ink recently, investors may take greater confidence in the top Wall Street upgrades this week. 
Via InvestorPlace
Gene Therapy Breakthroughs On The Horizon
Vertex Pharmaceuticals and CRISPR Therapeutics, alongside bluebird bio, are penning a new chapter in the story of gene therapy for sickle cell disease. 
Via Talk Markets
3 Green Flags for Biotech Stocks in 2023 and Beyond
The industry is changing rapidly, and for the better. 
Via The Motley Fool
What 13 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
Why CRISPR Therapeutics Stock Is Jumping Today
Analysts continue to like this gene-editing stock. 
Via The Motley Fool
1 No-Brainer Cathie Wood Stock to Buy Hand Over Fist in August
Crispr Therapeutics could be incredibly undervalued right now. 
Via The Motley Fool
The 3 Most Undervalued Cathie Wood Stocks to Buy Now: August 2023
Even if Cathie Wood stocks in ARK fell from grace, these three portfolio picks remain undervalued and ideal investments. 
Via InvestorPlace
Missed Out on CRISPR Therapeutics? My Best Biotech Stock to Buy and Hold
CRISPR Therapeutics is an intriguing biotech stock to consider now. 
Via The Motley Fool
3 Reasons to Buy CRISPR Therapeutics Stock, and 1 Reason to Sell
This company is in a critical period, and it could soon grow significantly. 
Via The Motley Fool
Ready to Buy the Dip? CRISPR Therapeutics Stock Is a Smart Buy
Its shares tumbled due to factors outside its control, but the biotech still has substantial long-term potential. 
Via The Motley Fool
Cathie Wood Buys Roblox, Palantir Dips — Ark Invest Seizes Buying Opportunities Following Earnings Reports
Via Benzinga
The Latest Analyst Ratings for CRISPR Therapeutics
Via Benzinga
The 3 Best Biotech Stocks to Buy in August
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news. 
Via InvestorPlace
2 Supercharged Growth Stocks That Could Make You Richer
These two biotechs are poised for a sustained period of growth. 
Via The Motley Fool
2 Great Stocks Under $100 to Buy and Hold for 10 Years
Neither has performed well over the past year, but investors would do well to focus on the longer term. 
Via The Motley Fool
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in today’s session. Paymentus Holdings, Inc. (NYSE: PAY) shares rose 29.4% to... 
Via Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser... 
Via Benzinga
3 Biotech Stocks That Analysts Are Drooling Over
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. 
Via InvestorPlace
3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now
Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites. 
Via InvestorPlace
Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline
Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 bill 
Via Benzinga
3 Hidden Penny Stocks That Could Turn $100 into $10,000
These penny stocks have multibagger upside potential with great margins of safety, according to Wall Street analysts. 
Via InvestorPlace
These 2 Stocks Are Heading for a Big Moment. Time to Buy?
Both stocks have climbed in the double digits this year. 
Via The Motley Fool
This 1 Innovation Could Make These 2 Biotechs Soar by 2030
Simplifying the cell therapy manufacturing process could be worth a lot of money. 
Via The Motley Fool
2 Soaring Stocks With More Upside Potential
Are these mid-cap stocks giants in the making? 
Via The Motley Fool
Is Now a Good Time to Buy CRISPR Therapeutics?
CRISPR shares have climbed more than 40% this year. 
Via The Motley Fool
3 Tech Stocks to Watch for Groundbreaking Innovations in 2030
If you’re a speculative investor here are three companies that are on the leading edge of what may be groundbreaking innovations by 2030. 
Via InvestorPlace
2 Monster Stocks to Buy Without Any Hesitation
These players each bring in billions of dollars in earnings every year. 
Via The Motley Fool
Cathie Wood Is Buying These 3 Growth Stocks Hand Over Fist. Should You?
The captain of innovation-focused investing can't seem to get enough of these beaten-down growth stocks. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.